RBC Capital Sticks to Their Buy Rating for Design Therapeutics (DSGN)
I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Leonid Timashev maintained a Buy rating on Design Therapeutics (DSGN) with a $20 price target. The stock closed at $12.76. Craig-Hallum also issued a Buy rating with a $22 target. Analyst consensus remains Strong Buy, with an average price target of $24.71, implying significant upside potential.
RBC Capital analyst Leonid Timashev maintained a Buy rating on Design Therapeutics on August 3 and set a price target of $20.00. The company’s shares closed yesterday at $12.76.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Timashev covers the Healthcare sector, focusing on stocks such as Insmed, Alkermes, and ADC Therapeutics. According to TipRanks, Timashev has an average return of 24.0% and a 60.25% success rate on recommended stocks.
Design Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $24.71, which is a 93.65% upside from current levels. In a report released on August 4, Craig-Hallum also maintained a Buy rating on the stock with a $22.00 price target.